A Comprehensive Review on Pros and Cons of Corticosteroid Treatment to Manage Nephrotic Syndrome
Article Sidebar
Main Article Content
Abstract
Protein leakage through urine, at a level exceeding 3.5g per 1.7m^2 of body area per day, is a symptom characteristic of Nephrotic syndrome. It's a diverse condition with symptoms including edema, hypoalbuminemia (≤ 25g/L), albumin excretion greater than 40 mg/m^2 per hour, uPCR ≥ 2,000 mg/g or 3+ protein in urine test. Springtime is when this syndrome is more common. A detailed literature review was conducted by using credible databases and scientific journals. This review concludes that in nephrotic syndrome, which is caused by metabolic and genetic defects, patients have to face proteinuria, edema, hyperlipidemia, and hypoalbuminemia. This study additionally focuses on the use of corticosteroids to treat nephrotic syndrome and the proper doses needed for effective therapy. Our study identified the complications related to nephrotic syndrome including the syndrome itself and post-treatment complications. Corticosteroids have been reported to side effect and relapse of nephrotic syndrome has also been identified as a health issue.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Pakistan Journal Emerging Science and Technologies (PJEST) in collaboration with Govt. Islamia Graduate College Civil Lines Lahore, Pakistan is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Kalantari, S., Nafar, M., &Rezaei-Tavirani, M. (2013). Urinary proteomics in nephrotic syndrome. Journal of Paramedical Sciences, 4(4), 108-115. https://doi.org/10.22037/jps.v4i4.5007
Lombel, R. M., Gipson, D. S., &Hodson, E. M. (2013). Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatric nephrology, 28(3), 415-426. https://doi.org/10.1007/s00467-012-2310-x
Kakar, S., Kumar, V., & Singh, R. (2017). Latest research progress on acute nephrotic syndrome. Journal of Acute Disease, 6(6), 255. https://doi.org/10.4103/2221-6189.221288
I.S. Daehn and J.S. Duffield, "The glomerular filtration barrier: a structural target for novel kidney therapies," Nat. Rev. Drug Discovery, vol. 20, pp. 770–788, 2021. https://doi.org/10.1038/s41573-021-00242-0
Andolino, T. P., & Reid-Adam, J. (2015). Nephrotic syndrome. Pediatrics in review, 36(3), 117-25. https://doi.org/10.1542/pir.36-3-117
Bierzynska, A., &Saleem, M. (2017). Recent advances in understanding and treating nephrotic syndrome. F1000Research, 6. https://doi.org/10.12688/f1000research.10165.1
Mukhi, D., Nishad, R., Menon, R. K., &Pasupulati, A. K. (2017). Novel actions of growth hormone in podocytes: implications for diabetic nephropathy. Frontiers in medicine, 4, 102. https://doi.org/10.3389/fmed.2017.00102
Sinha, A., &Bagga, A. (2012). Nephrotic syndrome. The Indian Journal of Pediatrics, 79(8), 1045-1055. https://doi.org/10.1007/s12098-012-0776-y
Vukojevic, K., Raguz, F., Saraga, M., Filipovic, N., Bocina, I., Kero, D., & Saraga-Babic, M. (2018). Glomeruli from patients with nephrin mutations show increased number of ciliated and poorly differentiated podocytes. Actahistochemica, 120(8), 748-756. https://doi.org/10.1016/j.acthis.2018.08.015
Kaneko, K., Tsuji, S., Kimata, T., Kitao, T., Yamanouchi, S., & Kato, S. (2015). Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes. World Journal of Pediatrics, 11(1), 21-28. https://doi.org/10.1007/s12519-015-0003-9
Gordillo, R., & Spitzer, A. (2009). The nephrotic syndrome. Pediatrics in review, 30(3), 94. https://doi.org/10.1542/pir.30-3-94
Noone, D. G., Iijima, K., & Parekh, R. (2018). Idiopathic nephrotic syndrome in children. The Lancet, 392(10141), 61-74. https://doi.org/10.1016/S0140-6736(18)30536-1
Dinçel, N., Yılmaz, E., Kaplan Bulut, İ., Hacıkara, Ş., & Mir, S. (2015). The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome. Renal failure, 37(8), 1267-1272. https://doi.org/10.3109/0886022x.2015.1073051
Lane, B. M., Cason, R., Esezobor, C. I., &Gbadegesin, R. A. (2019). Genetics of childhood steroid sensitive nephrotic syndrome: an update. Frontiers in pediatrics, 7, 8. https://doi.org/10.3389/fped.2019.00008
Çiçek, H. (2024), Introductory Chapter: An Overview of Nephritis, Nephrotic Syndrome, and Nephrosis, Novel Topics in the Diagnosis, Treatment, and Follow-Up of Nephritis, Nephrotic Syndrome, and Nephrosis. https://doi.org/10.5772/intechopen.113372.
Hogg, R. J., Portman, R. J., Milliner, D., Lemley, K. V., Eddy, A., & Ingelfinger, J. (2000), Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics, 105(6), 1242-1249. https://doi.org/10.1542/peds.105.6.1242
Menon, S. (2019). Acute kidney injury in nephrotic syndrome. Frontiers in pediatrics, 6, 428. https://doi.org/10.3389/fped.2018.00428
McCaffrey, J., Lennon, R., & Webb, N. J. (2016). The non-immunosuppressive management of childhood nephrotic syndrome. Pediatric Nephrology, 31(9), 1383-1402. https://doi.org/10.1007/s00467-015-3241-0
El Mashad, G. M., Ibrahim, S. A. E. H., & Abdelnaby, S. A. A. (2017). Immunoglobulin G and M levels in childhood nephrotic syndrome: two centers Egyptian study. Electronic physician, 9(2), 3728. https://doi.org/10.19082/3728
Kelly, G. S., & Brady, T. M. (2016). A Child with Nephrotic Syndrome and Abdominal Pain. Clinical pediatrics, 55(7), 683-685. https://doi.org/10.1177/0009922815598861
Hull, R. P., & Goldsmith, D. J. (2008). Nephrotic syndrome in adults. BMJ, 336(7654), 1185-1189. https://doi.org/10.1136/bmj.39576.709711.80
Sharifi-Mood, B., Khajeh, A., Metanat, M., & Rasouli, A. (2015). Epidemiology of meningitis studied at a university Hospital in Zahedan, South-Eastern Iran. International Journal of Infection, 2(2). https://dx.doi.org/10.17795/iji-23634
Ray, E. C., Rondon-Berrios, H., Boyd, C. R., &Kleyman, T. R. (2015). Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension. Advances in chronic kidney disease, 22(3), 179-184. https://doi.org/10.1053/j.ackd.2014.11.006
Cadnapaphornchai, M. A., Tkachenko, O., Shchekochikhin, D., & Schrier, R. W. (2014). The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. Pediatric nephrology, 29(7), 1159-1167. https://doi.org/10.1007/s00467-013-2567-8
Weng, F. L., Shults, J., Herskovitz, R. M. (2005). Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol, 20, 56–63. https://doi.org/10.1007/s00467-004-1694-7
Yang, M., Pan, X., Liang, Z., Huang, X., Duan, M., Cai, H., & Chen, L. (2019). Clinical Features of Nephrotic Syndrome with Cerebral Hemorrhage. Medical science monitor: international medical journal of experimental and clinical research, 25, 2179. https://doi.org/10.12659/msm.912466
Candan, C., Canpolat, N., Gökalp, S., Yıldız, N., Turhan, P., Taşdemir, M., & Çalışkan, S. (2014). Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome. Pediatric nephrology, 29(1), 95-102. https://doi.org/10.1007/s00467-013-2608-3
Eddy, A. A., & Symons, J. M. (2003). Nephrotic syndrome in childhood. The lancet, 362(9384), 629-639. https://doi.org/10.1016/s0140-6736(03)14184-0
Vivarelli, M., Gibson, K., Sinha, A., and Boyer, O. (2023). Childhood nephrotic syndrome. The Lancet, 402(10404), 809-824. https://doi.org/10.1016/S0140-6736(23)01051-6
Ali, E. T. M., Makki, H. F., Abdelraheem, M. B., Makke, S. O., & Allidir, R. A. (2017). Childhood idiopathic steroid-resistant nephrotic syndrome at a Single Center in Khartoum. Saudi Journal of Kidney Diseases and Transplantation, 28(4), 851.
Jalanko, H. (2009). Congenital nephrotic syndrome. Pediatric nephrology, 24(11), 2121-2128. https://doi.org/10.1007/s00467-007-0633-9
Krishnan, C., Rajesh, T. V., Shashidhara, H. J., Jayakrishnan, M. P., & Geeta, M. G. (2017). Major infections in children with nephrotic syndrome. Int J ContempPediatr, 4(2), 346-50. http://dx.doi.org/10.18203/2349-3291.ijcp20170450
Wang, Y., Bu, J., Zhang, Q., Chen, K., Zhang, J., & Bao, X. (2015). Expression pattern of aquaporins in patients with primary nephrotic syndrome with edema. Molecular medicine reports, 12(4), 5625-5632. https://doi.org/10.3892/mmr.2015.4209
Frățilă, V. G., Lupușoru, G., Sorohan, B. M., Obrișcă, B., Mocanu, V., Lupușoru, M., and Ismail, G. (2024). Nephrotic syndrome: From pathophysiology to novel therapeutic approaches. Biomedicines, 12(3), 569. https://doi.org/10.3390/biomedicines12030569
Ellison, D. H. (2019). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 14(8), 1248-1257. https://doi.org/10.2215/cjn.09630818
M.T. Christian and A.P. Maxted (2022). Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome. Pediatr.Nephrol., 37, 37–47. https://doi.org/10.1007/s00467-021-04985-1
Qavi, A. H., Kamal, R., &Schrier, R. W. (2015). Clinical use of diuretics in heart failure, cirrhosis, and nephrotic syndrome. International journal of nephrology. https://doi.org/10.1155/2015/975934
Hoorn, E. J., & Ellison, D. H. (2017). Diuretic resistance. American Journal of Kidney Diseases, 69(1), 136-142. https://doi.org/10.1053/j.ajkd.2016.08.027
Toblli, J. E., Bevione, P., Di Gennaro, F., Madalena, L., Cao, G., & Angerosa, M. (2012). Understanding the mechanisms of proteinuria: therapeutic implications. International journal of nephrology, 13. https://doi.org/10.1155/2012/546039
J. Hoshino, "Renal rehabilitation: exercise intervention and nutritional support in dialysis patients," Nutrients, vol. 13, no. 5, p. 1444, 2021. https://doi.org/10.3390/nu13051444.
Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., & Russo, E. (2013). Corticosteroid-related central nervous system side effects. Journal of pharmacology & pharmacotherapeutics, 4(1), 94. https://doi.org/10.4103/0976-500x.120975
Deschênes, G., Dossier, C., & Hogan, J. (2019). Treating the idiopathic nephrotic syndrome: are steroids the answer? Pediatric Nephrology, 34(5), 777-785. https://doi.org/10.1007/s00467-018-3963-x
Schijvens, A. M., ter Heine, R., De Wildt, S. N., & Schreuder, M. F. (2019). Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology, 34(3), 389-403. https://doi.org/10.1007/s00467-018-3929-z
Yuzawa, Y., Yamamoto, R., Takahashi, K., Katafuchi, R., Tomita, M., Fujigaki, Y., & Urushihara, M. (2016). Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clinical and experimental nephrology, 20(4), 511-535. https://doi.org/10.1007/s10157-015-1223-y
Kuźma-Mroczkowska, E., Skrzypczyk, P., & Pańczyk-Tomaszewska, M. (2016). Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience. Central-European journal of immunology, 41(3), 243. https://doi.org/10.5114/ceji.2016.63122
Karunamoorthy, S., Thanigachalam, D., Jeyachandran, D., Ramanathan, S., Natarajan, G., & Thoppalan, B. (2019). The safety and efficacy of mycophenolatemofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study. Clinical Kidney Journal, 13(2), 179-183. https://doi.org/10.1093/ckj/sfz061
Prasad, N., Manjunath, R., Rangaswamy, D., Jaiswal, A., Agarwal, V., Bhadauria, D., & Gupta, A. (2018). Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: A prospective study. Indian journal of nephrology, 28(1), 46. https://doi.org/10.4103/ijn.ijn_240_16
Beck, L., Bomback, A. S., Choi, M. J., Holzman, L. B., Langford, C., Mariani, L. H., & Waldman, M. (2013). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. American Journal of Kidney Diseases, 62(3), 403-441. https://doi.org/10.1053/j.ajkd.2013.06.002
Brown, E. J., Pollak, M. R., & Barua, M. (2014). Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney international, 85(5), 1030-1038. https://doi.org/10.1038/ki.2014.48
Van Husen, M., & Kemper, M. J. (2011). New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatric nephrology, 26(6), 881-892. https://doi.org/10.1007/s00467-010-1717-5
Mühlig, A. K., Lee, J. Y., Kemper, M. J., Kronbichler, A., Yang, J. W., Lee, J. M., & Oh, J. (2019). Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects. Journal of clinical medicine, 8(6), 860 https://doi.org/10.3390/jcm8060860
S. N. Uwaezuoke. (2015). Steroid-sensitive nephrotic syndrome in children: triggers of relapse and evolving hypotheses on pathogenesis. Ital. J. Pediatr., 41, 19. https://doi.org/10.1186/s13052-015-0123-9
Wang, X. Q., Wang, L., Tu, Y. C., & Zhang, Y. C. (2018). Traditional Chinese medicine for refractory nephrotic syndrome: strategies and promising treatments. Evidence-Based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/8746349
Vivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017). Minimal change disease. Clinical Journal of the American Society of Nephrology, 12(2), 332-345. https://doi.org/10.2215/cjn.05000516
Atanda, A. T. (2012). Chapter 3: steroid-sensitive nephrotic syndrome in children. Kidney Int. Suppl, 2, 163-171. https://doi.org/10.1038/kisup.2012.16
Alsaran, K., Mirza, K., Al-Talhi, A., & Al-Kanani, E. (2017). Experience with second line drugs in frequently relapsing and steroid dependent childhood nephrotic syndrome in a large Saudi center. International Journal of Pediatrics and Adolescent Medicine, 4(2), 66-70. https://doi.org/10.1016/j.ijpam.2017.03.002
Samuel, E. M. K., Krishnamurthy, S., Bhanudeep, S., &Muske, S. (2017). Levamisole in frequently-relapsing and steroid-dependent nephrotic syndrome. Indian pediatrics, 54(10), 831-834. https://doi.org/10.1007/s13312-017-1144-9
Kuga, K., Nishifuji, K., & Iwasaki, T. (2008). Cyclosporine A inhibits transcription of cytokine genes and decreases the frequencies of IL-2 producing cells in feline mononuclear cells. Journal of Veterinary Medical Science, 70(10), 1011-1016. https://doi.org/10.1292/jvms.70.1011
Cattran, D. C., Alexopoulos, E., Heering, P., Hoyer, P. F., Johnston, A., Meyrier, A., & Praga, M. (2007). Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney international, 72(12), 1429-1447 https://doi.org/10.1038/sj.ki.5002553
Kudagammana, S. T., Thalgahagoda, S., Abeyagunawardena, S., Karunadasa, U. I., & Abeyagunawardena, A. S. (2017). Efficacy of Levamisole as a single agent in maintaining remission in steroid dependant nephrotic syndrome. Sri Lanka Journal of Medicine, 26(1). http://doi.org/10.4038/sljm.v26i1.26
Rahman, M. H., Huque, S. S., Rahman, M. A., & Uddin, G. M. (2016). Efficacy of Cyclophosphamide versus Cyclosporine in Frequent Relapse Nephrotic Syndrome–A Hospital Based Study. Journal of Pediatric Nephrology, 4(2), 60-64. https://doi.org/10.22037/jpn.v4i2.11716
Gruppen, M. P., Bouts, A. H., Jansen-van der Weide, M. C., Merkus, M. P., Zurowska, A., Maternik, M., & Schurmans, T. (2018). A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney international, 93(2), 510-518. https://doi.org/10.1016/j.kint.2017.08.011
Gao, C. L., & Xia, Z. K. (2017). Interpretation of guidelines for the diagnosis and treatment of steroid-resistant nephrotic syndrome. Chinese journal of pediatrics, 55(11), 810-812. https://doi.org/10.3760/cma.j.issn.0578-1310.2017.11.003
Kallash, M., Smoyer, W. E., & Mahan, J. D. (2019). Rituximab use in the management of childhood nephrotic syndrome. Frontiers in pediatrics, 7,178. https://doi.org/10.3389/fped.2019.00178
Fujinaga, S., & Sakuraya, K. (2017). Repeated administrations of rituximab along with steroids and immunosuppressive agents in refractory steroid-resistant nephrotic syndrome. Indian Pediatr, 54, 49-50. https://doi.org/10.1007/s13312-017-0996-3
Mori, K., Honda, M., & Ikeda, M. (2004). Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatric Nephrology, 19(11), 1232-1236. https://doi.org/10.1007/s00467-004-1584-z
Ehren, R., Benz, M. R., Doetsch, J., Fichtner, A., Gellermann, J., Haffner, D., & Konrad, M. (2018). Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolatemofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ open, 8(10). https://doi.org/10.1136/bmjopen-2018-024882
Saleem, M. A. (2019). Molecular stratification of idiopathic nephrotic syndrome. Nature Reviews Nephrology, 5(12), 750-765. https://doi.org/10.1038/s41581-019-0217-5
Ravani, P., Ponticelli, A., Siciliano, C., Fornoni, A., Magnasco, A., Sica, F., & Ghio, L. (2013). Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome. Kidney international, 84(5), 1025-1033. https://doi.org/10.1038/ki.2013.211
Bonanni, A., Calatroni, M., D'Alessandro, M., Signa, S., Bertelli, E., Cioni, M., & Bertelli, R. (2018). Adverse events linked with the use of chimeric and humanized anti‐CD20 antibodies in children with idiopathic nephrotic syndrome. British journal of clinical pharmacology, 84(6), 1238-1249. https://doi.org/10.1111/bcp.13548
Yu, C. C., Fornoni, A., Weins, A., Hakroush, S., Maiguel, D., Sageshima, J., & Campbell, K. N. (2013). Abatacept in B7-1–positive proteinuric kidney disease. New England Journal of Medicine, 369(25), 2416-2423. https://doi.org/10.1056/nejmoa1304572
W. Y. Ding, V. Kuzmuk, S. Hunter, A. Lay, B. Hayes, M. Beesley, M. A. Saleem. (2023). Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Science Translational Medicine, 15(708), 8226. https://doi.org/10.1126/scitranslmed.abc8226.
X. Zhang, Y. Jin, F. Liu, Q. Li, Y. Xie, G. Huang, J. Chen, X. He, S. He, H. Fu, J. Wang, H. Shen, J. Mao. (2024). Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome. Clinical Kidney Journal, 348. https://doi.org/10.1093/ckj/sfae348.
K. Merchant, S. Zanos, T. Datta-Chaudhuri. (2022). Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot study. Bioelectron Med, 8(1). https://doi.org/10.1186/s42234-021-00084-6.
R. Sharma, V. Prasad, E. T. McCarthy. (2007). Chymase increases glomerular albumin permeability via protease-activated receptor-2. Mol. Cell Biochem., 297, 161–169. https://doi.org/10.1007/s11010-006-9342-0.
R. Varghese and A. Majumdar. (2024). All-trans-retinoic acid and valproic acid: A combinatorial approach for the treatment of nephrotic syndrome. Current Research in Biotechnology, 7, 100181. https://doi.org/10.1016/j.crbiot.2024.100181.
Hara, H., & Hirano, D. (2018). Azithromycin suppressed relapses of idiopathic nephrotic syndrome in a child. Clinical kidney journal, 11(1), 54-55. https://doi.org/10.1093/ckj/sfx099
Banh, T. H., Hussain-Shamsy, N., Patel, V., Vasilevska-Ristovska, J., Borges, K., Sibbald, C., & Reddon, M. (2016). Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clinical Journal of the American Society of Nephrology, 11(10), 1760-1768. https://doi.org/10.2215/cjn.00380116
Hahn, D., Hodson, E. M., Willis, N. S., & Craig, J. C. (2020). Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, (3). https://doi.org/10.1002/14651858.CD001533.pub6
Bagga, A. (2008). Revised guidelines for management of steroid-sensitive nephrotic syndrome. Indian journal of nephrology, 18(1), 31. https://doi.org/10.4103/0971-4065.41289
Youssef, D. M., Al-atif, A. M. A., El-Khateeb, S. S. H., & Elshal, A. S. (2018). Evaluation of interleukin-18 in children with steroid-sensitive nephrotic syndrome before and after using levamisole. Saudi Journal of Kidney Diseases and Transplantation, 29(3), 591. https://doi.org/10.4103/1319-2442.235173
Yu, X., Ruan, L., Qu, Z., Cui, Z., Zhang, Y., Wang, X., & Liu, G. (2017). Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. Renal failure, 39(1), 688-697. https://doi.org/10.1080/0886022x.2017.1373130
Iijima, K., Hamahira, K., Tanaka, R., Kobayashi, A., Nozu, K., Nakamura, H., & Yoshikawa, N. (2002). Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney international, 61(5), 1801-1805. https://doi.org/10.1046/j.1523-1755.2002.00303.x
Mishra, O. P., Basu, B., Upadhyay, S. K., Prasad, R., & Schaefer, F. (2010). Behavioural abnormalities in children with nephrotic syndrome. Nephrology Dialysis Transplantation, 25(8), 2537-2541. https://doi.org/10.1093/ndt/gfq097
Al Salloum, A. A., Muthanna, A., Bassrawi, R., Al Shehab, A. A., Al Ibrahim, A., Islam, M. Z., & Alhasan, K. (2012). Long-term outcome of the difficult nephrotic syndrome in children. Saudi Journal of Kidney Diseases and Transplantation, 23(5), 965. https://doi.org/10.4103/1319-2442.100877
Gaur, S., Joseph, M., Nityanandam, S., Subramanian, S., Koshy, A. S., Vasudevan, A., & Iyengar, A. (2014). Ocular complications in children with nephrotic syndrome on long term oral steroids. The Indian Journal of Pediatrics, 81(7), 680-683. https://doi.org/10.1007/s12098-014-1338-2
Leroy, V., Baudouin, V., Alberti, C., Guest, G., Niaudet, P., Loirat, C., & Simon, D. (2009). Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. Pediatric Nephrology, 24(12), 2393-2400. https://doi.org/10.1007/s00467-009-1266-y
Donatti, T. L., Koch, V. H. K., Takayama, L., & Pereira, R. M. R. (2011). Effects of glucocorticoids on growth and bone mineralization. Jornal de pediatria, 87(1), 4-12. https://doi.org/10.2223/jped.2052
Park, S. J., & Shin, J. I. (2011). Complications of nephrotic syndrome. Korean journal of pediatrics, 54(8), 322-328. https://doi.org/10.3345/kjp.2011.54.8.322
Klein, G. L. (2015). The effect of glucocorticoids on bone and muscle. Osteoporosis and sarcopenia, 1(1), 39-45. https://doi.org/10.1016/j.afos.2015.07.008
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016). Long-term side effects of glucocorticoids. Expert opinion on drug safety, 15(4), 457-465. https://doi.org/10.1517/14740338.2016.1140743
Maeda, R., Kawasaki, Y., Ohara, S., Suyama, K., &Hosoya, M. (2018). Serum sickness with refractory nephrotic syndrome following treatment with rituximab. CEN case reports, 7(1), 69-72. https://doi.org/10.1007/s13730-017-0297-7
Grenda, R., Jarmużek, W., Rubik, J., Migdał, M., &Pronicki, M. (2015). Fatal rituximab‐associated lung injury syndrome in a patient treated with rituximab for recurrence of post‐transplant nephrotic syndrome. Pediatric transplantation, 19(5), 115-120. https://doi.org/10.1111/petr.12481
Spatafora, M., Bellini, T., Giordano, C., & Ghiggeri, G. M. (2015). A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome. Case Reports. https://doi.org/10.1136/bcr-2015-212694
Kopač, M. (2018). Nephrotic Syndrome in Children–Present State and Future Perspectives. Journal of Nephrology Research, 4(1), 139-145. http://dx.doi.org/10.17554/j.issn.2410-0579.2018.04.28
Nantarakchaikul, P., & Nimdet, K. (2015). An infantile exogenous Cushing syndrome caused by topical steroid. International journal of pediatric endocrinology, 2015(1), 45. https://doi.org/10.1186/1687-9856-2015-s1-p45
Ehren, R., Benz, M. R., Brinkkötter, P. T. (2021). Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy — short version of the updated German best practice guideline (S2e) — AWMF register no. 166-001, 6/2020. Pediatr Nephrol, 36, 2971–2985. https://doi.org/10.1007/s00467-021-05135-3.
G. S. Dhooria, S. Bhargava, D. Bhat. (2024). Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study. BMC Nephrol, 25, 296. https://doi.org/10.1186/s12882-024-03739-z.
A. M. Schijvens, N. Teeninga, E. M. Dorresteijn. (2021). Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8- and 12-weeks regimen using an individual patient data meta-analysis. Eur. J. Pediatr., 180, 2849–2859. https://doi.org/10.1007/s00431-021-04035-w.
K. A. W. Kashif, A. Ranjan, S. Kalra, U. D. S. Uttpal, and A. Malik. (2022). Clinicopathological spectrum and treatment outcome of idiopathic steroid-resistant nephrotic syndrome in children at a tertiary care center. Med. J. Armed Forces India, 78(3), 291-295. https://doi.org/10.1016/j.mjafi.2020.11.004.
Y. Welegerima, M. Feyissa, and T. Nedi. (2021). Treatment outcomes of pediatric nephrotic syndrome patients treated in Ayder Comprehensive Specialized and Mekelle General Hospitals, Ethiopia. Int. J. Nephrol. Renovascular Dis., 14, 149–156. https://doi.org/10.2147/IJNRD.S310567
Jafry, N., Ahmed, E., Mubarak, M., Kazi, J., & Akhter, F. (2012). Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults. Nephrology Dialysis Transplantation, 27(3), 1101-1106. https://doi.org/10.1093/ndt/gfr430